Narrowband ultraviolet B phototherapy for the treatment of pruritus induced by chronic liver disease and cholestasis

JRCT ID: jRCTs052180032

Registered date:29/01/2019

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: chronic liver disease or cholestasis including chronic hepatitis, cirrhosis, PSC, and PBC
• Date of first enrollment: 01/01/2019
• Target sample size: 30
• Study type: Interventional
• Intervention(s): Narrowband UVB phototherapy is performed once a week, starting at 0.3 to 0.5 J / cm2 and increasing by 0.05 to 0.1 J / cm2 (up to 1.5 J / cm2) depending on the therapeutic effect. The total number of phototherapy should be 24 at the maximum, and if sufficient effect is obtained and patient's consent is obtained, phototherapy can be terminated at the judgment of the attending physician.

Outcome(s)

Primary Outcome

Utility of narrowband ultraviolet B phototherapy for patients with
refractory hepatic pruritus

• Secondary Outcome: None

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

Patients eligible for preregistration were those: (i) with
chronic liver disease or cholestasis including chronic hepatitis, cirrhosis, PSC, and PBC; (ii) who were at least 20 years of age at the time of
informed consent; (iii) mean VAS>50 mm in one week, or VAS of >20 mm on 5 or more days per week, or pruritus scores >3 on 4 or more days per week.

• Exclude criteria: Patients with psychiatric disorder, dementia, dermatosis, or chronic renal disease.

Related Information

• Primary Sponsor: Takai Atsushi
• Secondary Sponsor: Eso Yuji
• Source(s) of Monetary Support: MSD